Skip to main content
Defiance International

VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

In vivo/preclinical record. Journal of neuroinflammation, 2016.

  • Animal
  • 2016

Authorship

Exact sentences from the abstract. No machine-written text is on this page. No person reviewed it.

Source: the abstract of PMID 27357191. Checked Verification: Evidence verified by machine against declared source

This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.

Verify a lot

Evidence verified by machine against declared source

Open declared source

Key facts

Design
Not reported
System
Animal
Scale
Not reported
Comparator
Present
Journal
Journal of neuroinflammation
Year
2016
PMID
27357191
Verification
Evidence verified by machine against declared source The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Full-text availability
Abstract only

Technical summary

Research question

Here, we investigated the involvement of VPAC1 in the development of EAE using a VPAC1-deficient mouse model.

Participants or experimental system

EAE was induced in wild-type (WT) and VPAC1 knockout (KO) mice using myelin oligodendrocyte glycoprotein 35–55 (MOG35–55), and clinical scores were assessed continuously over 30 days.

Intervention or exposure

Two hundred nanograms of Pertussis toxin (List Biological Laboratories) was administered intraperitoneally (i.p.) to the mice on the immunization day as well as 2 days later.

Comparator

The percent donor composition was determined by measuring the percentage of CD45.2 (donor) vs. CD45.1 (recipient) in whole blood cells in the recipient mice before EAE induction.

Outcomes examined

The contribution of VPAC1 expression in the immune system to the development of EAE was evaluated by means of adoptive transfer and bone marrow chimera experiments.

Not reported in the declared source: Methods, Study design, Study scale, Key findings. Not published in this record: Key findings.

Limitations and uncertainty

In our studies with a VPAC1 antagonist treatment, a long-term administration before EAE induction led to a lack of EAE similar to that found in VPAC1 KO mice.

Cite

Cite the study

VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.
Abad C, Jayaram B, Becquet L et al. Journal of neuroinflammation. 2016. PMID 27357191

The study and its abstract belong to their authors and publisher. Cite them for anything the study found.

Report an error

If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.

The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.

The report form runs in the interactive page. Open this record with scripts enabled to send a report.

Corrections on this record

No correction has been recorded for this record.

Method sheet

No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.